ATR mediates cisplatin resistance in a p53 genotype-specific manner.
The protein kinase encoded by the ataxia telangiectasia and Rad3-related (ATR) gene is activated by DNA-damaging agents that are frequently used as anticancer therapeutics. Inhibition of ATR expression in cultured cancer cells has been demonstrated to increase sensitivity to chemotherapeutic drugs, including the DNA-crosslinking agent cisplatin. Cisplatin is a widely used and effective drug, but its use is associated with significant toxicity. Here, we demonstrate that genetic inhibition of ATR expression selectively enhanced cisplatin sensitivity in human colorectal cancer cells with inactivated p53. A knock-in strategy was used to restore wild-type p53 in cells harboring wild-type or mutant ATR alleles. Knock-in of functional p53 in ATR-deficient cells restored checkpoint function, suppressed apoptotic pathways and markedly increased clonogenic survival after cisplatin treatment. These results suggest that a strategy that combines specific inhibitors of ATR and conventional therapies might promote synthetic lethality in p53-deficient tumors, and thus minimize toxicity to normal tissues.
Department of Radiation Oncology and Molecular Radiation Sciences, The Johns Hopkins University School of Medicine, Baltimore, MD 21231, USA.
N
N
Sangster-Guity
B H
BH
Conrad
N
N
Papadopoulos
F
F
Bunz
D000970:Antineoplastic Agents / Q000494:pharmacology*; D017209:Apoptosis / Q000235:genetics; D064007:Ataxia Telangiectasia Mutated Proteins; D018797:Cell Cycle Proteins / Q000037:antagonists & inhibitors / Q000235:genetics*; D045744:Cell Line, Tumor; D002945:Cisplatin / Q000494:pharmacology*; D019008:Drug Resistance, Neoplasm / Q000235:genetics*; D055785:Gene Knockdown Techniques; D006801:Humans; D009369:Neoplasms / Q000235:genetics*; D017346:Protein Serine-Threonine Kinases / Q000037:antagonists & inhibitors / Q000235:genetics*; D016159:Tumor Suppressor Protein p53 / Q000235:genetics
D000970:Antineoplastic Agents; D018797:Cell Cycle Proteins; D016159:Tumor Suppressor Protein p53; C576597:ATR protein, human; D064007:Ataxia Telangiectasia Mutated Proteins; D017346:Protein Serine-Threonine Kinases; D002945:Cisplatin
Science. 2007 May 25;316(5828):1160-6
17525332
Genes Dev. 2009 Aug 15;23(16):1895-909
19608766
Nat Rev Cancer. 2009 Oct;9(10):714-23
19730431
Nat Cell Biol. 2006 Jan;8(1):37-45
16327781
Proc Natl Acad Sci U S A. 2009 Mar 10;106(10):3964-9
19225112
Cell. 2000 Sep 15;102(6):849-62
11030628
Nat Rev Cancer. 2002 Aug;2(8):594-604
12154352
Curr Opin Cell Biol. 2009 Apr;21(2):245-55
19230643
Mol Pharmacol. 2005 Dec;68(6):1636-44
16126823
Oncogene. 2006 Aug 31;25(39):5359-69
16619043
Nat Genet. 2009 Aug;41(8):891-8
19620979
Nat Rev Mol Cell Biol. 2008 Aug;9(8):616-27
18594563
Clin Cancer Res. 2007 Apr 1;13(7):1955-60
17404075
Cell. 2006 Aug 11;126(3):529-42
16901786
Hum Mol Genet. 2004 Dec 15;13(24):3127-38
15496423
Mol Cancer Ther. 2007 Apr;6(4):1406-13
17431119
Nature. 2004 Nov 18;432(7015):316-23
15549093
Cancer Res. 1995 Nov 15;55(22):5187-90
7585571
Nat Genet. 2009 Oct;41(10):1144-9
19718024
Pharmaceuticals (Basel). 2010 Apr 28;3(5):1311-1334
27713304
Proc Natl Acad Sci U S A. 2008 Dec 30;105(52):20752-7
19091954
Mol Cell. 2007 Mar 9;25(5):725-38
17349958
EMBO J. 2004 Nov 24;23(23):4583-94
15526030
Science. 1998 Nov 20;282(5393):1497-501
9822382
J Biol Chem. 2003 Jun 6;278(23):20475-9
12654917
Trends Biochem Sci. 2006 Jul;31(7):402-10
16774833
Mol Cancer Ther. 2008 Aug;7(8):2394-404
18723486
PLoS Genet. 2010 Feb 26;6(2):e1000863
20195506
Genes Dev. 1999 Jan 15;13(2):152-7
9925639
Mol Cell Biol. 2010 Apr;30(7):1620-33
20123963
Oncogene. 2007 Apr 19;26(18):2535-42
17043640
Nat Cell Biol. 2009 Sep;11(9):1128-34
19731416
EMBO J. 1998 Jan 2;17(1):159-69
9427750
J Biol Chem. 2008 Mar 7;283(10):6572-83
18162465
Mol Pharmacol. 2009 Jul;76(1):208-14
19403702
Oncogene. 2010 Nov 18;29(46):6149-59
20729914
Cell Cycle. 2005 Jan;4(1):131-9
15539958
Cancer Cell. 2007 Feb;11(2):175-89
17292828
Cell Cycle. 2007 Feb 15;6(4):414-7
17312392
Anticancer Drugs. 2000 Jul;11(6):419-32
11001382
Oncogene. 2003 Oct 20;22(47):7486-95
14576853
J Clin Invest. 1999 Aug;104(3):263-9
10430607
Nucleic Acids Res. 2005 Oct 07;33(18):e158
16214806
Nat Genet. 2003 Apr;33(4):497-501
12640452
Mol Cell. 2010 Oct 8;40(1):34-49
20932473
Cell Cycle. 2005 Oct;4(10):1428-34
16138010
Cancer Res. 2003 Apr 1;63(7):1550-4
12670903
Trends Cell Biol. 2002 Nov;12(11):509-16
12446112